Skip to content
Screener

Discontinued — last reported Q4 '20

Total Revenue at other companies

Pfizer logo
PfizerPFE
$15.03B+2.6%
Amgen logo
AmgenAMGN
$10.05B+9.5%
Incyte logo
IncyteINCY
$1.67B+37.7%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$0-100%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$350K-48.3%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$41M-74.4%

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$7.14B+366%
Enterprise value$6.92B+372%

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×
Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The source filing: Cogent Biosciences, Inc.’s 10-K, filed March 15, 2022. Open the filing →

Filed
Mar 15, 2022, 8:51 AM EDT
Fiscal year
FY2021
Accession
0001564590-22-010238

FAQ

What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.